Equitable Oncology
INTRODUCING EQUITABLE ONCOLOGY
The story behind Equitable Oncology, why we exist and how we are working to help more people access cancer treatment.
Read Introducing Equitable Oncology →16 Sep 2026
News & Resources
stay informed about Equitable Oncology
Follow the progress of Equitable Oncology as we advance our programmes, build partnerships and grow our organisation. We will share important milestones and developments as we work towards helping more people access cancer treatment.
LATEST NEWS
The latest from Equitable Oncology.
Recent posts:
- Introducing Equitable Oncology, the story behind why we exist and how we're working to help more people access cancer treatment.
- Equitable Oncology officially launches with a clear purpose: helping more people access cancer treatment.
- K5K selected as Equitable Oncology’s first programme, putting the Equitable Oncology Model into action.
- Equitable Oncology achieves registered charity status, marking an important milestone for the organisation and its charitable purpose.
Equitable Oncology
EQUITABLE ONCOLOGY OFFICIALLY LAUNCHES
A new New Zealand registered charity has officially launched, bringing together science, philanthropy and collaboration to help more people access cancer treatment.
Read more15 Aug 2026
Our Work
K5K SELECTED AS EQUITABLE ONCOLOGY’S FIRST PROGRAMME
Equitable Oncology has selected K5K, an innovative cancer immunotherapy, as the first programme to be advanced through the Equitable Oncology Model.
Read more29 Aug 2026
Our News
EQUITABLE ONCOLOGY ACHIEVES REGISTERED CHARITY STATUS
Equitable Oncology has been officially registered as a New Zealand charity, supporting our work to help more people access cancer treatment.
Read more29 Aug 2026
information,
publications &
key documents
Equitable Oncology is committed to transparency, knowledge sharing and making information accessible.
Explore publications, reports, scientific information and key organisational documents that support our work and charitable purpose. As Equitable Oncology grows, this collection will continue to expand.
frequently asked questions
Straightforward answers to common questions about Equitable Oncology, the Equitable Oncology Model and our lead programme.
Exploreglossary
Plain-language explanations of terms used across Equitable Oncology's work, our Model and our programmes.
Explorescientific publications
Research papers, scientific publications and resources supporting Equitable Oncology programmes.
Kode technology
Explore selected scientific publications relating to Kode Technology.
Kode Technology Illustrated Technical Manual
Stephen M. Henry, Alexander B. Tuzikov, Nicolai V. Bovin. 1st edition, 2023. ISBN 978-1-9911998-0-5.
Kode Technology – a universal cell surface glycan modification technology
Stephen M. Henry, Nicolai V. Bovin. Journal of the Royal Society of New Zealand. 2019;49(2):100–113.
Rapid one-step biotinylation of biological and non-biological surfaces
Stephen Henry, Eleanor Williams, Katie Barr, Elena Korchagina, Alexandr Tuzikov, Natalia Ilyushina, Sidahmed A. Abayzeed, Kevin F. Webb, Nicolai Bovin. Scientific Reports. 2018;8:2845.
COVID-19 antibody screening with SARS-CoV-2 red cell kodecytes using routine serologic diagnostic platforms
R. Nagappan, W.A. Flegel, K. Srivastava, E.C. Williams, I. Ryzhov, A. Tuzikov, O. Galanina, N. Shilova, G. Sukhikh, H. Perry, N.V. Bovin, S.M. Henry. Transfusion. 2021;61:1171–1180.
Revealing and quantifying polyclonal anti-A,B specificity in ABO histo-blood groups
Stephen Henry, Holly Perry, Polina Obukhova, Tatiana Tyrtysh, Ivan Ryzhov, Nicolai Bovin, Suvro Sankha Datta. Transfusion. 2026;66(5):965–975.
Kode Immuno-Educer (KIE)
Explore selected scientific publications relating to AGI-134, an earlier-generation Kode Immuno-Educer evaluated in human clinical studies.
AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models
Stephen M. Shaw, Jenny Middleton, Kim Wigglesworth, Amber Charlemagne, Oliver Schulz, Melanie S. Glossop, Giles F. Whalen, Robert Old, Mike Westby, Chris Pickford, Rinat Tabakman, Irit Carmi-Levy, Abi Vainstein, Ella Sorani, Arik A. Zur, Sascha A. Kristian. Cancer Cell International. 2019;19:346.
Cancer Immunotherapy by Intratumoral Injection of α-gal Glycolipids
Giles F. Whalen, Mary Sullivan, Bilal Piperdi, Wahid Wasseff, Uri Galili. Anticancer Research. 2012;32(9):3861–3868.
BioLineRx Announces Results from Phase 1/2a Study of AGI-134 in Metastatic Solid Tumors
BioLineRx Ltd. 20 December 2022. Phase 1/2a clinical study results – NCT03593226.
strategic briefings
Briefings, discussion papers and strategic publications supporting engagement with government, policymakers, philanthropists, partners and other stakeholders.
plans & reports
Strategic plans, annual reports and organisational publications.
governance
Governance documents, policies and organisational frameworks supporting Equitable Oncology's governance and accountability.
Documents will be added here as they become available.
media resources
Resources for journalists and media covering Equitable Oncology, the Equitable Oncology Model and our lead programme K5K. For media enquiries, interview requests, or further information, please contact Christine Gill, Chief Executive.
stay connected
Follow Equitable Oncology for the latest news, programme updates and progress towards helping more people access cancer treatment.
Follow Us